A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Public ClinicalTrials.gov record NCT04612725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Study identification
- NCT ID
- NCT04612725
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Interventions
- Benralizumab Biological
- Placebo and Benralizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2020
- Primary completion
- Oct 12, 2022
- Completion
- Mar 27, 2023
- Last update posted
- Mar 12, 2024
2020 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85260 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Mission Viejo | California | 92691 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Miami | Florida | 33173 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Columbus | Georgia | 31904 | — |
| Research Site | Ypsilanti | Michigan | 48197 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Cincinnati | Ohio | 45236 | — |
| Research Site | Norman | Oklahoma | 73071 | — |
| Research Site | Austin | Texas | 78745 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04612725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04612725 live on ClinicalTrials.gov.